These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
140 related items for PubMed ID: 18076947
21. Anterior apical biopsy: is it useful for prostate cancer detection? Orikasa K, Ito A, Ishidoya S, Saito S, Endo M, Arai Y. Int J Urol; 2008 Oct; 15(10):900-4; discussion 904. PubMed ID: 18657203 [Abstract] [Full Text] [Related]
22. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. Ploussard G, Dubosq F, Boublil V, Allory Y, de la Taille A, Vordos D, Hoznek A, Abbou CC, Salomon L. J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310 [Abstract] [Full Text] [Related]
23. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores. Miyake H, Kurahashi T, Takenaka A, Hara I, Fujisawa M. Urol Int; 2007 Oct; 79(4):302-6. PubMed ID: 18025846 [Abstract] [Full Text] [Related]
24. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514 [Abstract] [Full Text] [Related]
25. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ. J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844 [Abstract] [Full Text] [Related]
26. The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy. Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, Martini M, Pansadoro V. J Urol; 2004 Jan; 171(1):197-9. PubMed ID: 14665875 [Abstract] [Full Text] [Related]
27. Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. Abouassaly R, Tan N, Moussa A, Jones JS. J Urol; 2008 Sep; 180(3):911-4; discussion 914. PubMed ID: 18635220 [Abstract] [Full Text] [Related]
28. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol. Abouassaly R, Lane BR, Jones JS. Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385 [Abstract] [Full Text] [Related]
29. Prostate cancer volume at biopsy predicts clinically significant upgrading. Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA. J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180 [Abstract] [Full Text] [Related]
30. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. J Urol; 2006 Feb; 175(2):485-8. PubMed ID: 16406977 [Abstract] [Full Text] [Related]
31. PCA3: a molecular urine assay for predicting prostate biopsy outcome. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. J Urol; 2008 Apr; 179(4):1587-92. PubMed ID: 18295257 [Abstract] [Full Text] [Related]
32. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed? Pepe P, Fraggetta F, Galia A, Grasso G, Piccolo S, Aragona F. Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023 [Abstract] [Full Text] [Related]
33. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A, Montorsi F, Graefen M, Huland H, Karakiewicz PI. Cancer; 2008 Nov 15; 113(10):2695-703. PubMed ID: 18853417 [Abstract] [Full Text] [Related]
34. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, Netto GJ. J Urol; 2007 May 15; 177(5):1736-40. PubMed ID: 17437801 [Abstract] [Full Text] [Related]
35. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Pepe P, Aragona F. Urology; 2007 Dec 15; 70(6):1131-5. PubMed ID: 18158033 [Abstract] [Full Text] [Related]
36. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. Lane BR, Zippe CD, Abouassaly R, Schoenfield L, Magi-Galluzzi C, Jones JS. J Urol; 2008 May 15; 179(5):1746-50; discussion 1750. PubMed ID: 18343412 [Abstract] [Full Text] [Related]
37. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K. Eur Urol; 2007 Sep 15; 52(3):715-23. PubMed ID: 17337114 [Abstract] [Full Text] [Related]
38. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. Philip J, Ragavan N, Desouza J, Foster CS, Javlé P. BJU Int; 2004 Jun 15; 93(9):1218-20. PubMed ID: 15180609 [Abstract] [Full Text] [Related]
39. Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report. Rocco B, de Cobelli O, Leon ME, Ferruti M, Mastropasqua MG, Matei DV, Gazzano G, Verweij F, Scardino E, Musi G, Djavan B, Rocco F. Eur Urol; 2006 May 15; 49(5):827-33. PubMed ID: 16426731 [Abstract] [Full Text] [Related]
40. Tissue-marking scheme for a cost-effective extended prostate biopsy protocol. Firoozi F, Nazeer T, Fisher HA, Kaufman RP, White MD, Mian BM. Urol Oncol; 2009 May 15; 27(1):21-5. PubMed ID: 18367125 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]